XOMA Ltd. (
Q2 2011 Earnings Call
August 4, 2011 4:30 pm ET
Carol DeGuzman – IR
Steven Engle – Chairman and CEO
Fred Kurland – VP, Finance and CFO
Alan Solinger – VP, Clinical Immunology
Liana Moussatos – Wedbush Securities
Christopher James – MLV
Ross Sweeney [ph] – RBC Capital Markets
Good day, ladies and gentlemen, and welcome to the XOMA second quarter 2011 financial results conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. (Operator instructions) As a reminder, this conference call is being recorded. I would now like to introduce your host for today’s conference, Carol DeGuzman, Senior Director of Investor Relations. Ms. DeGuzman, you may begin.
Thank you, operator. And good afternoon, everyone. A short while ago, we issued our news release, which included financial results for the quarter ended June 30, 2011 and a general business update. Our quarterly report on Form 10-Q was filed with the Securities and Exchange Commission this afternoon. Each document will be available on the XOMA website at xoma.com. Today’s webcast also can be accessed via our website and will be available for replay until the close of business on November 4, 2011.
Joining me on today’s call is Steven Engle, Chairman and Chief Executive Officer; and Fred Kurland, Vice President and Chief Financial Officer. Also joining us is Dr. Alan Solinger, our Vice President of Clinical Immunology. We wish to remind all listeners that certain statements concerning product, conduct or availability of results of clinical trials, entry into a O52 development partnership or potential licensing and collaboration arrangements or other aspects of product developments or that otherwise relate to future periods are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.